Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 15Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 2Immunoblastic Lymphadenopathy 2Triple Negative Breast Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Breast Neoplasms 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2romidepsin 1decitabine and cedazuridine drug combination 1Vincristine 1Tomography, X-Ray Computed 1Prednisone 1Oxaliplatin 1Gemcitabine 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell, Peripheral × romidepsin × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡